Hemispherx BioPharma, Inc (HEB) Short Interest Down 22.2% in September
Hemispherx BioPharma, Inc (NYSE:HEB) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 223,168 shares, a decrease of 22.2% from the September 15th total of 286,805 shares. Approximately 1.1% of the company’s stock are short sold. Based on an average daily volume of 83,996 shares, the short-interest ratio is currently 2.7 days.
Shares of Hemispherx BioPharma (NYSE:HEB) opened at 1.16 on Wednesday. Hemispherx BioPharma has a 12-month low of $0.72 and a 12-month high of $2.64. The stock has a 50 day moving average price of $1.43 and a 200-day moving average price of $1.53. The stock’s market cap is $24.06 million.
Hemispherx BioPharma (NYSE:HEB) last issued its quarterly earnings results on Monday, August 15th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter. During the same quarter last year, the business earned ($0.02) EPS.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/hemispherx-biopharma-inc-heb-short-interest-down-22-2-in-september.html
About Hemispherx BioPharma
Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.
Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.